The effect of HFE genotype (wild-type, heterozygosity for C282Y and H63D mutations, and other genotypes) on hepcidin-25 in CHD patients is shown in Figure 1A. Hepcidin-25 was lower in patients with HFE mutations than in those without (p = 0.01), in particular in those carrying the C282Y mutation or homozygous for the H63D mutation (p = 0.0004). This evidence concerns the gene HAMP and coronary artery disorder.